Ilimaquinone exhibits antitumor activity via the GADD153-mediated signaling pathway; induces vesiculation of the Golgi apparatus; possesses antiviral, antibacterial, and anti-inflammatory activities; and demonstrates concentration-dependent anti-proliferative effects against various cancer cell lines, including prostate cancer (PC-3 and LNCaP), non-small cell lung cancer (A549), and hepatocellular carcinoma (Hep3B) cells.